| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
66,002,000 |
| Market
Cap: |
6.97(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$43.96 - $108.78 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 486 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Blueprint Medicines is a precision therapy company that is inventing medicines for people with cancer and blood disorders. Co. is delivering ITS approved medicines, AYVAKIT®/AYVAKYT® (avapritinib) and GAVRETO® (pralsetinib), to patients in the U.S. and Europe, and Co. is globally developing various programs for systemic mastocytosis lung cancer and other genomically defined cancers, and cancer immunotherapy. Co.'s drug discovery approach combines its biological insights with its proprietary compound library and chemistry capabilities to design therapies, with the goal of delivering clinical benefit to patients based on the genetic driver of their disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,100 |
| Total Buy Value |
$0 |
$0 |
$0 |
$48,378 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
140,074 |
185,302 |
263,382 |
381,554 |
| Total Sell Value |
$12,910,702 |
$16,666,116 |
$20,928,894 |
$27,757,920 |
| Total People Sold |
12 |
12 |
12 |
12 |
| Total Sell Transactions |
22 |
29 |
39 |
64 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Haviland Kate |
Chief Operating Officer |
• – – |
2020-11-16 |
4 |
AS |
$100.27 |
$41,010 |
D/D |
(409) |
42,838 |
|
-7% |
|
| Haviland Kate |
Chief Operating Officer |
• – – |
2020-11-16 |
4 |
OE |
$36.05 |
$14,744 |
D/D |
409 |
43,247 |
|
- |
|
| Rossi Christina |
Chief Commercial Officer |
• – – |
2020-11-03 |
4 |
S |
$99.69 |
$34,393 |
D/D |
(345) |
20,020 |
|
-7% |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-11-03 |
4 |
S |
$95.97 |
$545,196 |
D/D |
(5,522) |
3,562 |
|
-7% |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-11-03 |
4 |
OE |
$9.46 |
$52,238 |
D/D |
5,522 |
9,084 |
|
- |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-11-02 |
4 |
S |
$99.11 |
$443,815 |
D/D |
(4,478) |
3,562 |
|
-7% |
|
| Rowland Charles A Jr |
Director |
– • – |
2020-11-02 |
4 |
OE |
$9.46 |
$42,362 |
D/D |
4,478 |
8,040 |
|
- |
|
| Boral Anthony L. |
Chief Medical Officer |
• – – |
2020-10-23 |
4 |
OE |
$8.80 |
$116,667 |
D/D |
9,183 |
28,147 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2020-10-19 |
4 |
AS |
$105.00 |
$572,775 |
D/D |
(5,455) |
3,562 |
|
-4% |
|
| Goldberg Mark Alan |
Director |
– • – |
2020-10-19 |
4 |
OE |
$19.53 |
$106,536 |
D/D |
5,455 |
9,017 |
|
- |
|
| Haviland Kate |
Chief Operating Officer |
• – – |
2020-10-16 |
4 |
AS |
$100.55 |
$1,349,848 |
D/D |
(13,334) |
42,838 |
|
-4% |
|
| Haviland Kate |
Chief Operating Officer |
• – – |
2020-10-16 |
4 |
OE |
$36.05 |
$480,691 |
D/D |
13,334 |
56,172 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2020-10-07 |
4 |
AS |
$100.00 |
$545,400 |
D/D |
(5,454) |
3,562 |
|
-3% |
|
| Goldberg Mark Alan |
Director |
– • – |
2020-10-07 |
4 |
OE |
$19.53 |
$106,517 |
D/D |
5,454 |
9,016 |
|
- |
|
| Hurley Ariel |
Principal Accounting Officer |
• – – |
2020-10-07 |
4 |
AS |
$100.00 |
$60,000 |
D/D |
(600) |
9,984 |
|
-3% |
|
| Hurley Ariel |
Principal Accounting Officer |
• – – |
2020-10-07 |
4 |
OE |
$8.80 |
$5,280 |
D/D |
600 |
10,584 |
|
- |
|
| Albers Jeffrey W. |
CEO and President |
• • – |
2020-10-07 |
4 |
AS |
$99.17 |
$495,850 |
D/D |
(5,000) |
141,434 |
|
-3% |
|
| Albers Jeffrey W. |
CEO and President |
• • – |
2020-10-07 |
4 |
OE |
$8.80 |
$44,000 |
D/D |
5,000 |
146,434 |
|
- |
|
| Dorsch Marion |
Chief Scientific Officer |
• – – |
2020-10-06 |
4 |
AS |
$99.00 |
$455,400 |
D/D |
(4,600) |
15,250 |
|
4% |
|
| Dorsch Marion |
Chief Scientific Officer |
• – – |
2020-10-06 |
4 |
OE |
$37.11 |
$170,706 |
D/D |
4,600 |
19,850 |
|
- |
|
| Lydon Nicholas |
Director |
– • – |
2020-10-01 |
4 |
AS |
$92.06 |
$913,595 |
D/D |
(9,815) |
37,425 |
|
7% |
|
| Namouni Fouad |
President, R & D |
• – – |
2020-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
32,500 |
32,500 |
|
- |
|
| Dorsch Marion |
Chief Scientific Officer |
• – – |
2020-09-23 |
4 |
AS |
$89.00 |
$409,400 |
D/D |
(4,600) |
15,250 |
|
10% |
|
| Dorsch Marion |
Chief Scientific Officer |
• – – |
2020-09-23 |
4 |
OE |
$37.11 |
$170,706 |
D/D |
4,600 |
19,850 |
|
- |
|
| Hurley Ariel |
Principal Accounting Officer |
• – – |
2020-09-23 |
4 |
AS |
$90.00 |
$126,000 |
D/D |
(1,400) |
9,984 |
|
10% |
|
565 Records found
|
|
Page 12 of 23 |
|
|
0.80 (0.75%) 
